Impact Objectives
• Establish a working group of experts on antibiotic stewardship and research design to determine the best way to design, analyse and report antibiotic stewardship interventions
• Formulate recommendations for the optimal design of future research in the field of antibiotic stewardship
Improving antibiotic stewardship

Professor Martin Llewelyn and Dr Valentijn Schweitzer discuss antibiotic stewardship and explain why there is an urgent need to develop recommendations for better research in this field
Could you start by defining 'antibiotic stewardship' and explain why is it important?
ML: Antibiotic resistance is one of the greatest challenges facing the world. Bacteria are increasingly resistant to the antibiotics we use to treat and prevent common infections. Overuse of antibiotics in medical treatment is one major driver of antibiotic resistance. The term 'antibiotic stewardship' refers to using antibiotics in ways which minimises their impact on antibiotic resistance without compromising individual patient treatment -making sure that we will continue to be able to use effective antibiotics in the future. As much as 30 per cent of human antibiotic use may be unnecessary and healthcare systems around the world are aiming to achieve substantial reductions in unnecessary antibiotic prescribing through better antibiotic stewardship. Emergence of antibiotic-resistant bacteria is now a critical issue in medicine. This rapid emergence of resistant bacteria has endangered the efficacy of antibiotics, posing a substantial threat to human health and placing a significant financial burden on healthcare systems.
Reducing medical use of antibiotics is one important way to reduce the selection pressure that drives resistance. Antibiotics can be overused in different ways, including prescribing an antibiotic when it is not necessary, prescribing more than one when one would be enough, prescribing broadly acting agents when more specific agents could be used, and continuing treatment longer than necessary.
IMPROVING ANTIBIOTIC STEWARDSHIP
In all these different ways, a significant proportion of antibiotics currently prescribed to patients are unnecessary. It is now clearly established that overuse of antibiotics is associated with increased risk of antibiotic resistance, both in populations and in individual patients. The challenge is how to use antibiotics more prudently but still make sure that patients get the effective antibiotic treatment they need. The term 'antibiotic stewardship' describes strategies to meet this challenge.
According to Professor Martin Llewelyn, the problem is that we do not have the evidence we need to tell us which antibiotic stewardship strategies we should be using. 'The situation arises out of very real issues with how to design research studies in the field of antimicrobial stewardship,' he explains. 'There has been an exponential increase in the number of published papers in this field of research, but the quality of these data -measured by the simple 
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Dr Valentijn Schweitzer is a medical doctor and PhD candidate at the Epidemiology of Infectious Diseases Department of University Medical Centre Utrecht. His PhD tract focuses on antimicrobial stewardship and community-acquired pneumonia under the guidance of Professor Marc Bonten. Schweitzer is currently involved in a large multicentre trial on stewardship in community-acquired pneumonia patients. After completing his PhD, he will start residency training in clinical microbiology.
RESEARCH RECOMMENDATIONS
From this research, some key findings have emerged. The team has proposed a novel theoretical framework for antimicrobial stewardship trials where four aspects of the intervention must be evaluated: its basis in theory and evidence, the intervention setting, the intervention features and the intervention aims. The team then proposes a series of key design questions that the researchers should answer in order to make the best study design decisions.
The final step is to set out a series of specific consensus recommendations for researchers. Already, several important insights have emerged. ' We recommend that future studies should always specify a clinical outcome to be measured to address concern that reducing antibiotic exposure might be detrimental to the patients being treated. This should sit alongside process outcomes to show that the stewardship intervention has reduced antibiotic use in the way the intervention intended,' Llewelyn reveals. 'We also set a benchmark for situations in which large, multicentre, controlled studies are not feasible but there is still a need for evidence to guide practice. Single centre observational studies have the potential to deliver valuable evidence -but only when they include properly conducted interrupted time series analysis.'
At present, the CASE Working Group is taking steps to actively disseminate its guidance, for example through conferences and publications. By exposing its findings to a wide range of scientists and stakeholders, the group hopes to make a significant economic and societal impact. With an international research team that consists of experts in the fields of clinical stewardship, adult medicine, paediatrics, statistics and implementation research, Llewelyn believes that their guidance to other researchers will be both thorough and authoritative.
SAVING LIVES
If current antibiotic practices continue unchanged, it is estimated that bacteria will continue to become more resistant so that, by 2050, antimicrobial resistance will be responsible for up to 10 million annual deaths. This rise in morbidity does not just come at tremendous human cost; it will also lead to a reduction in Gross Domestic Product (GDP) of up to 3.5 per cent, costing the world an estimated US $100 trillion. No one wants these dreadful statistics to become a reality. The only way to stop antimicrobial resistance from progressing is to adopt an effective, evidence-based antibiotic stewardship approach -a feat that requires international consensus on best antimicrobial stewardship research practices.
If the CASE Working Group's recommendations are followed, the team anticipates stronger antimicrobial stewardship studies with far fewer limitations. 'The potential impact is huge if our findings are translated into better antibiotic research,' Llewelyn states. 'The key thing for us is getting the best research done to produce the evidence clinicians need to use antibiotics precisely.' Convincing healthcare professionals to re-evaluate their views and prescription policies regarding antibiotics is an uphill battle. However, by coming together as a united front, researchers from all around the world can pave a way to stopping antimicrobial resistance growth and, in turn, save millions of patient lives. l The potential impact is huge if our findings are translated into better antibiotic research. The key thing for us is getting the best research done to produce the evidence clinicians need to use antibiotics precisely
